Wednesday, January 24, 2024
Oncodesign Services (ODS), a leading Contract Research Organization specializing in drug discovery and preclinical services, is expanding globally through the acquisition of ZoBio, a Dutch Contract Research Organization known for its expertise in biophysics-based small molecule drug discovery.
This acquisition enables ODS to enhance its capabilities in small molecule discovery, offering a comprehensive and integrated suite of services to support customers' innovative programs from target validation to candidate selection.
ODS has a strong reputation for expertise in preclinical evaluation across major disease areas such as oncology and immuno-inflammation. The company excels in medicinal chemistry, computational chemistry, DMPK, pharmaco-imaging, and molecular radiotherapy. ODS has successfully developed several drug candidates that have advanced to the clinical development phase in collaboration with partner clients.
ZoBio, established over 19 years ago, is recognized for scientific excellence and innovation in biophysics-based drug discovery. The company's platform includes protein sciences, biophysical and functional assays, structural biology, and a diverse small molecule fragment library, contributing to the advancement of multiple compounds into clinical trials.
Following the acquisition, ODS and ZoBio collectively employ nearly 280 professionals across various locations. This strategic move positions ODS to become a European leader in Drug Discovery, offering fully integrated services and solutions with an emphasis on quality, scientific creativity, operational excellence, and transparent client relationships.
Dr. Fabrice Viviani, CEO of ODS, expressed gratitude to the executive team and investors, welcoming ZoBio to the group. The collaboration aims to strengthen ODS's small molecule drug discovery preclinical services, providing expertise from gene to IND and leveraging cutting-edge skills and technologies.
Dr. Gregg Siegal, CEO of ZoBio, expressed enthusiasm about combining ZoBio's Fragment Based Drug Discovery platform with ODS's expertise. The integration is expected to enhance capabilities across the drug discovery pipeline, and both companies look forward to delivering the best to their clients through this strategic partnership.
Source: prnewswire.com
